We are dedicated to delivering first-in-class cancer cell directed therapies, innovations in immuno-oncology and smart therapeutic combinations.
Find out more about our clinical development programme, below.
Explore the videos and materials below to learn more about how Boehringer Ingelheim are taking cancer on.
Xentuzumab, BI 836858, BI 836880, BI 894999, BI 754091, BI754111, BI 891065, BI 907828, BI 905677, BI 765063 and BI 1361849 are investigational compounds and have not been approved. Their safety and efficacy have not been established.
© 2019 Boehringer Ingelheim International GmbH. All rights reserved.
Page last updated: June 2019